Article
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).
Nature communications - 19 Jan 2026
Shen Bo, Wang Chun, Zhang Liqin, Zhu Yingying, Zhang Xing, Wang Xiaoxuan, Guo Zhen, Wang Li, Wang Xiaohua, Zhu Liqun, Zhou Yun, Liao Danting, Shi Meiqi
Abstract excerpt
Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates first-line double-dose firmonertinib (160 mg/day) in adults with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.